Trichostatin A (TSA)

製品コードS1045

Trichostatin A (TSA)化学構造

分子量(MW):302.4

Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。

サイズ 価格(税別) 在庫  
JPY 53784.00 あり
JPY 41002.00 あり
JPY 74202.00 あり
JPY 144420.00 あり

カスタマーフィードバック(5)

  • Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

    (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Trichostatin A (TSA)は一種のHDAC阻害剤で、無細胞試験でIC50値が1.8 nM程度です。
ターゲット
HDAC [1]
(Cell-free assay)
~1.8 nM
体外試験

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 M{P4d2Z2dmO2aX;uJGF{e2G7 MmryNE44|ryP NE\KUFgzPGh? M3v1XIV1cGGwb3y= NVvSXFZV\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NVfre3JlOjV5OEewO|k>
TE13 MWHGeY5kfGmxbjDBd5NigQ>? MlPFNE4{|ryP NVG4U3dHOjSq MkfteZAuemWpdXzheIV{KFKDU2PGOWEhdGW4ZXy= NE\WdVEzPTV5OU[2OS=>
TE13 MVLBdI9xfG:|aYOgRZN{[Xl? NX[5PItTOC5|zszN MmHDNlRp MlzubY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? NFTJSngzPTV5OU[2OS=>
MEFs NGLLT4hHfW6ldHnvckBCe3OjeR?= MkPpOe69VQ>? NX7BSnd[OT[q M1PxZ4lv[3KnYYPld{B1cGViRWDFR{BifHSjY3jt[Y51NCCWaYKg[IVtcX[ncomgZY5lKHSqZTDl[oZq[2mnbnP5JI9nKHCnZHXzeIFtKG[xcn3heIlwdg>? NEWxT5QzPTR6Mk[zOC=>
SW480  M{DId2Z2dmO2aX;uJGF{e2G7 MnL6NE4y|ryP MnnkOFhp MoTQSG1UVw>? M4nNbJJmfmW{c3XzJGVOXA>? M{f3VlI2PDN2OUm3
PC3  MlLsSpVv[3Srb36gRZN{[Xl? NH3sd5oxNjIQvF2= M2S3TlQ5cA>? MknXSG1UVw>? M3TQWJJmfmW{c3XzJGVOXA>? MnzNNlU1OzR7OUe=
SW480  MlrWSpVv[3Srb36gRZN{[Xl? NXHZWmtmOC5zzszN MmfrOFhp NWnkOZhjTE2VTx?= MYrheJRmdnWjdHXzJIlvfmG|aX;uJIFv\CCvaXfyZZRqd25? NF\2RZgzPTR|NEm5Oy=>
PC3  NF7hdlRHfW6ldHnvckBCe3OjeR?= NH;CVHoxNjIQvF2= NXPZVFlkPDiq NX\XNIE5TE2VTx?= NWXRc5NO[XS2ZX71ZZRmeyCrbo\hd4lwdiCjbnSgcYloemG2aX;u MVOyOVQ{PDl7Nx?=
SW480  NVrWSllSTnWwY4Tpc44hSXO|YYm= M4\IfVAvOc7:TR?= M3HKc|Q5cA>? NU\oUJpSTE2VTx?= NHmxRY1qdmS3Y3XzJIlv[3KnYYPlJI9nKEiGQVOxJIFv\CCKRFHDNkBwdiCVbIXnJIdmdmW|IIDyc41wfGW{ NGTNSJYzPTR|NEm5Oy=>
PC3  Mo\MSpVv[3Srb36gRZN{[Xl? NITjNlMxNjIQvF2= MnXaOFhp MW\EUXNQ MVHpcoR2[2W|IHnuZ5Jm[XOnIH;mJGhFSUNzIHHu[EBJTEGFMjDvckBUdHWpIHflcoV{KHC{b33veIVz NXrzOol7OjV2M{S5PVc>
A431 NGrGXFZCeG:ydH;zbZMhSXO|YYm= MVmyM|ExNzVyL{GwNI5O NVzhSoZoPDiq NF6ySHlFVVOR MnW0bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3Sq MljONlU{PzFyNkm=
A431 NFnvS2pHfW6ldHnvckBCe3OjeR?= M{ntcFUxdk1? Mk\lNk83NzF{L{K0bC=> M3\0fmROW09? M3iyXoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= MnnhNlU{PzFyNkm=
MDA-MB-231 M4ThSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXiwMVYxOG6P M2rSRlI1cA>? Mkj5SG1UVw>? MX3JR|UxKG:oIEGwNI5O MYKyOVE6Ojd{MR?=
MCF7 MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyNE03ODCwTR?= NWfRXmoxOjSq NXS5PIxLTE2VTx?= NHTjdo1KSzVyIH;mJFc2dk1? MUCyOVE6Ojd{MR?=
SKOV-3 NV\lc4VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vr[FEuOTEQvF2= NHrJbZkzPGh? M3PFcGROW09? NXfNbmpNUUN3MDDv[kA2NjcQvF2= NUHZOJhbOjVzNkm0PVE>
A549 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moj1NU0yOM7:TR?= M2n1XFI1cA>? NFXIPWZFVVOR MYDJR|UxKG:oIEOuNu69VQ>? MXiyOVE3QTR7MR?=
SKOV-3 NWPobYV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4UG5UOC5zLUJOwG0> Ml34OFhp MWXEUXNQ NH7QVpdKSzVyIH;mJFAvP87:TR?= MmTGNlUyPjl2OUG=
A549 NITYVpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCwMlEuOc7:TR?= NYTkW3IyPDiq NVjLNG0xTE2VTx?= NXP2c2c2UUN3MDDv[kAxNjJ6zszN NEDhXnMzPTF4OUS5NS=>
SKOV-3 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEH4XZMxNjBzLUCuPe69VQ>? NXrv[oFiPzKq NH7IRpNFVVOR NYPqeY06UUN3MDDv[kAxNjN{zszN NV7RW2pLOjVzNkm0PVE>
A549 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37ZR|AvODFvMD65{txO MmrMO|Jp M2P1SmROW09? MnXOTWM2OCCxZjCwMlA3|ryP MnPQNlUyPjl2OUG=
HeLa NFu4b4JHfW6ldHnvckBCe3OjeR?= NUnnPYJjOjVybl2= MXmxOog> MV;EUXNQ NELW[XFqdmO{ZXHz[ZMhS1mSMVGxJI1TVkFiZYjwdoV{e2mxbtMg NGPIe|YzPTFzNk[4PC=>
CNE2 NYP5Z5kxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m1dVExOC14MEDuUS=> NH7IN2EzPC92OD:3Nog> Ml[ybY5pcWKrdIOgeIhmKHC{b3zp[oVz[XSrb36gbY4h[SC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Ml3SNlQ6Pjl7MEG=
PC3 NXz3RmJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[zTlExOC1zMECwcm0> NF3ncFIzPGh? M1nHcGlEPTBib3[gN|Axdk1? M2X2N|I1QDV2NkW4
LNCaP NV;ROVVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\ROGIyODBvMUCwNI5O MYSyOIg> M{fi[2lEPTBib3[gN|Axdk1? NH\Hcm0zPDh3NE[1PC=>
HeLa  NVr4Z4JOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfOfVcz|ryP Mke2OFhp NFHC[Zhl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgZYJwfXRiMkWl NHrBUFczPDh2NkGzOS=>
HMEC-1  NHfObHFHfW6ldHnvckBCe3OjeR?= Ml7mN|Axdk1? NIW0fIIzPGh? MnTYbY5kemWjc3XzJIV5eHKnc4Ppc44hd2cEoG\FS2ZTO8LibWLORS=> M{jIR|I1PzFyNkOx
HeLa NYDGcXVmTnWwY4Tpc44hSXO|YYm= NEDCcIkydU1? NH:2Um8xNjWq MknsZYJwdGm|aHXzJJRp\SC2b4ThcEBJTEGFIHHjeIl3cXS7 MmDENlQ4ODd2N{S=
ACP02 M1;MT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWnjW|V{OjVyL{O1NE82ODCwTR?= NECybWgzPGh? M2qwNIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? MXWyOFY3QDV2Nx?=
ACP03 M4LYXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLTZ3VWOjVyL{O1NE82ODCwTR?= Mk\QNlRp MX\k[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHlib3[gZZBxem:6aX3heIVtgSB5MNMgKUBifCB{NUFCpI5O MXOyOFY3QDV2Nx?=
U87 GBM M4HR[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXmxNFAwOzByL{WwNEBvVQ>? NG\jSZA4OiCq MnO2NVAxLSCndHjhco9t MVLy[YR2[2W|IH3lZY4h[2WubDDueY1j\XJiYomgN|EtKDV2LDDhcoQhPTkEoDW= MljxNlQ1PjR6NEG=
U87 GBM NG[1d4hHfW6ldHnvckBCe3OjeR?= NFHFS2QyODBxNUCwJG5u MmLZOFghcA>? NITVVmgyODBnIHX0bIFvd2x? MljxTY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 MmrKNlQ1PjR6NEG=
RPE NIP6PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTXSnExNjJxMD60M|AvQC9zIN88US=> MV2yOE81QC95MjDo M2ToNGROW09? NFL3dIVqdmirYnn0d{B1cGVicILvcIln\XKjdHnvckBjgSClZXzsJIN6[2ynIHHydoV{fA>? MVmyOFQ2PjZyMh?=
HT29  M3vGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFn0cIcyQDBibl2= NX\HOotQPzJiaB?= MVHJR|UxKG:oIEG4NEBvVQ>? MYOyOFM3QDJ4NR?=
hMSCs M4HDe2Z2dmO2aX;uJGF{e2G7 NGDlSmI3NjJ3IH7N MoiyNlQhcA>? NHXsfZhFVVOR MkLqd5Ri[mmuaYrld{BJcXO2b37lJGFk\XS7bHH0bY9vKGGwZDD0bIUhTXiycnXzd4lwdiCxZjDQcJVzcXCxdHXueEBI\W6ncx?= NWfxPYZKOjR|MUKzOVY>
Huh7  MnvySpVv[3Srb36gRZN{[Xl? MWCwMlEwOC53L{GuNEDPxE1? NF;HOJIzPGh? M{TnR5N2eHC{ZYPz[ZMhYVSKRFOyJIdmdmViZYjwdoV{e2mxbh?= M3fnWVI1OjZ7Nkey
SKOV3 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHqxeVkxNjB3LUKg{txO MUSxNE8zPC92ODDo NYfhU4VFTE2VTx?= MWHt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M2LrZlI1OjJ|OECx
A2780 MoXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHpb|AxNjB3LUKg{txO NXf6PHZHOTBxMkSvOFghcA>? MXTEUXNQ NIe2eZVu\WSrYYTld{Boem:5dHigZZJz\XO2IHnuJIEh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= MlK2NlQzOjN6MEG=
SRA01/04  NGj3NFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HX[|AvOiEQvF2= MlXaOFghcA>? NX\JSYgyTE2VTx?= M4LXUZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ NVnXPW5xOjRzNUe4O|g>
HLEB3 M37ydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\6e2wxNjJizszN MWS0PEBp M3jWVGROW09? MVrzeZBxemW|c3XzJINmdGxicILvcIln\XKjdHnvckB1cHKxdXfoJJN2eHC{ZYPzbY5oKHSqZTDQTVNMN0GtdDygdFM5VUGSSzDhcoQhTVKNMT:yJJNq\26jbHnu[{Bx[XSqd3H5dy=> NGq4PHMzPDF3N{i3PC=>
SRA01/04  NXXlbGdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk[4NE41NzBwODFOwG0> MVO0PEBp MnyzSG1UVw>? M4HhTolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? Ml;qNlQyPTd6N{i=
HLEB3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLifYdROC52L{CuPEDPxE1? NV\oUIxiPDhiaB?= M1XQXmROW09? M1n0UIlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? MlXpNlQyPTd6N{i=
HCT116 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlr6NE4zKM7:TR?= MmXlNVIhcA>? Mk\z[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= NYrBToJsOjRzMkKyN|E>
CA46 M{e5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHTZoc3Oy94L{GyM|I1NzR6IH7N MUG0PEBp NXmyfYl1cW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDheEAzPCCjbnSgOFghdk4EoB?= M33IVlI1ODZ2OUWx
PMNs MlTDSpVv[3Srb36gRZN{[Xl? M3;LV|MxKG6P MXK0PEBp M1Hyd4lvcGmkaYTzJIVn\mW{b3P5eI9{cXNuIFjERWMh[WO2aY\peJkh[W6mIGLhZ{Bi[3Srdnn0fS=> NWe5SJpvOjN7OEi2NVc>
H1299 NYe0SY17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\5NeKh|ryPwrC= M17EO|I1NzR6L{eyJIg> NX\LPHNY\XSqYX7vcC=> MnrMbY5kemWjc3XzJINmdGxiZHXheIgh[W[2ZYKgNlRp NH21O5czOzlzNk[wPS=>
A549 NFe0eoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml2xNE4zPS9yLkWvNUDPxE1? MYCyOE81QC95MjDo MWHleIhidm:u NETnbWRqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NVW2RXNiOjN6Nke5PVE>
H1299 MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUOwMlI2NzBwNT:xJO69VQ>? NYj6OGlSOjRxNEivO|IhcA>? NWDkfGZ1\XSqYX7vcC=> NFfJUnFqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ MUWyN|g3Pzl7MR?=
A549 NWOwblZ{SXCxcITvd4l{KEG|c3H5 MmnGNE42NzFizszN M1GxUVQ5KGh? MlrO[ZRp[W6xbB?= NFnTU|BqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Ml[4NlM5Pjd7OUG=
H1299 NF\UbHdCeG:ydH;zbZMhSXO|YYm= M3PsU|AvPS9zIN88US=> M4G2V|Q5KGh? M122N4V1cGGwb3y= NIf4e|JqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Ml\VNlM5Pjd7OUG=
SUM149PT MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjZbHFbOi95LkWvNVAh|ryP M{n1XFQ5KGh? MWPEUXNQ NGP0[pFqdmS3Y3XzJINmdGxiZHXheIgh[XRiMjFOwG0hcW6|ZX7zbZRqfmWueR?= NFLq[5UzOzd7Mk[zPC=>
SUM190PT MlPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P3fFUxNzFyMD:yOVAhdk1? MmTKOFghcA>? NIDGNJJFVVOR M1TpfYlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? M{XXTlI{Pzl{NkO4
HCT1 NFvoeoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjBNE4zNzFwMD:1MlAh|ryP NIDxVoUyOi9{ND:zOk81QCCq MVfpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= NXjkRVdvOjN5N{CwNFA>
Lovo NWrWXVd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXEbmQxNjJxMT6wM|UvOCEQvF2= MVuxNk8zPC9|Nj:0PEBp MWjpcoR2[2W|IHPlcIwh\GWjdHigbY4h[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M33ZZVI{PzdyMECw
AGS M33rfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLsNE4xOTVvMTFOwG0> Moi3O|IhcA>? MV\pcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= NGPuZ4wzOzd2NUCyOC=>
Huh7 NUnOV4xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnne2E5OSEQvF2= NH\KbVQzPCCq MlO4SG1UVw>? Mn\2doVlfWOnczDhZo92fCB{MDWgeoli[mmuaYT5xsA> NFe0VmUzOzZ2M{mzNy=>
ECC1 NV3wOItsTnWwY4Tpc44hSXO|YYm= NEfTbWk2ODBibl2= MUC1JIQ> MV7EUXNQ M2DYZ4lv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NHX1cWQzOzV|MEe2PS=>
HEC1A NH\VOnVHfW6ldHnvckBCe3OjeR?= M4XUOVUxOCCwTR?= NIXGTW82KGR? M331VGROW09? NFvnT2VqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= Mke3NlM2OzB5Nkm=
EN1 MV\GeY5kfGmxbjDBd5NigQ>? NVrmVJp2PTByIH7N NVzzWnBHPSCm M1[0cGROW09? MYXpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? MV:yN|U{ODd4OR?=
MFE296 NUnMZndYTnWwY4Tpc44hSXO|YYm= NETlSo82ODBibl2= MlfVOUBl Ml2ySG1UVw>? MUnpcoR2[2W|IFyxR2FOyqCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEWtRZpiSw>? M37KeFI{PTNyN{[5
HASMCs NF;5WFFHfW6ldHnvckBCe3OjeR?= M3H6N|AuPTByIH7N NFvZW2E3KGR? M3jNbYRwf25vcnXneYxifGW|IITo[UBmgHC{ZYPzbY9vKG:oIFjBSGMh[W6mIHPlcIwhfmmjYnnsbZR6 M1W0c|I{PTF6NE[3
U373 NGfJZXJHfW6ldHnvckBCe3OjeR?= MY[wMlI2NzBwNT:xJO69VQ>? M3PsclI1KGh? MYfpcoNz\WG|ZYOgVHIuSiCneIDy[ZN{cW:wIHPvMZRz\WG2bXXueEB4cXSqIEXBfoFlSw>? MUOyN|Q4PDF5MR?=
ARN8  MWHGeY5kfGmxbjDBd5NigQ>? NFHTcHoxNjB3LUKg{txO NGn3PWkzPCCq MVzy[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZicEWzMYRmeGWwZHXueEBo\W6nczDifUBPfXSuaX6tNy=> Ml3MNlM1PzB3NEC=
MCF7 MYPGeY5kfGmxbjDBd5NigQ>? Mo\WNE4xPS1{IN88US=> NWLzPGFqOjRiaB?= NFXkNJFz\WS3Y3XzJJRp\SCrbnT1Z5Rqd25ib3[gdFU{NWSncHXu[IVvfCCpZX7ld{BjgSCQdYTsbY4uOw>? Mnf3NlM1PzB3NEC=
H1299  NFzUe4FHfW6ldHnvckBCe3OjeR?= M1L1Z|AvOzQkgKOxxsDDvU1? MmjHNlQwPDhiaB?= MYjEUXNQ NFnjfpBqdmO{ZXHz[ZMhTS2lYXTo[ZJqdiCycn;0[YlvKGyndnXsd{Bld3OnIHTldIVv\GWwdHz5 MYCyN|Q3OTl5NR?=
H1299 MWPGeY5kfGmxbjDBd5NigQ>? MWewMlUh|ryP MmrsOFghcA>? MWrEUXNQ NGP5bIRqdmirYnn0d{B1cGVibXnndoF1d3K7IIDveIVvfGmjbDDjc41jcW6nIIfpeIghe2muaXLpcolv NFTZN3YzOzR4MUm3OS=>
H1299 MVnGeY5kfGmxbjDBd5NigQ>? M3;SPVAvPSEQvF2= NInYU|Q1QCCq MWXEUXNQ MlHPbY5pcWKrdIOgeIhmKGmwdnHzbZZmdmW|c9MgJINwdWKrbnWge4l1cCC|aXzpZolvcW5? MoHUNlM1PjF7N{W=
MG-63  NETYdY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXGwMlMh|ryP M4nVUVEzNTl4IHi= NVPjNmo6TE2VTx?= MmPJbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= M3Xj[FI{PDVzOEG3
LM8 MojFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTCVGVjOC5|IN88US=> MVKxNk06PiCq NFXiS3lFVVOR Mne2bY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHPvMZRz\WG2bXXueEB4cXSqIH3leIZwem2rbh?= NYO0SoJyOjN2NUG4NVc>
K562 MoO2SpVv[3Srb36gRZN{[Xl? MX:wMlUh|ryP NH3ZVXozPCCq M{nxb4V1cGGwb3y= MUfk[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> MYSyN|Q{ODl3Nx?=
HEL NXX6Vot3TnWwY4Tpc44hSXO|YYm= NICzPXIxNjVizszN Mm\ENlQhcA>? M4W2SoV1cGGwb3y= M{G3T4Rm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv M1LuTFI{PDNyOUW3
HL60 MX\BdI9xfG:|aYOgRZN{[Xl? NVjWTYgyOSEQvF2= NFLSPGozPCCq MWrpcoR2[2W|wrDj[YxtKGSnYYTo NYSz[5hlOjN2MEC1NVk>
KG1 MWXBdI9xfG:|aYOgRZN{[Xl? MoOwNUDPxE1? MXKyOEBp M2ryUYlv\HWlZYRCpINmdGxiZHXheIg> M{jvN|I{PDByNUG5
Kazumi MnL4RZBweHSxc3nzJGF{e2G7 NWrncVk1OSEQvF2= NIi0SnQzPCCq NXzUVGR5cW6mdXPld:Kh[2WubDDk[YF1cA>? MUGyN|QxODVzOR?=
K562 MoXJRZBweHSxc3nzJGF{e2G7 MmfnNUDPxE1? NHHoUW4zPCCq NVLmdHJycW6mdXPld:Kh[2WubDDk[YF1cA>? M2rvOlI{PDByNUG5
THP1 MnvURZBweHSxc3nzJGF{e2G7 NGC0RlEyKM7:TR?= MVOyOEBp NGXC[lRqdmS3Y3XzxsBk\WyuIHTlZZRp MVSyN|QxODVzOR?=
SH-SY5Y MVTGeY5kfGmxbjDBd5NigQ>? NXW2[Hd1OjVyIH7N M2\qSVE3KGh? NG\xWolkcGGwZ3XzJIV5eHKnc4Ppc44heGG2dHXyckBw\iCpZX7ld{Bqdn[xbI\l[EBqdiClaH;s[ZN1\XKxbDDzfY51cGW|aYOsJJVxfGGtZTDhcoQh\W[obIX4 MXmyN|MzPjR{Mh?=
HEK293 NY[2SFR7TnWwY4Tpc44hSXO|YYm= NIHsZ5IyKML3TdMg MmLQNVghcMLi MUnpcohq[mm2czD0bIUhc2GuaYLpck04NW2nZHnheIVlKHKnY4L1bZRu\W62IH;mJJN6dnCqaXzpck0yKGGpZ4Ll[4F1\XNiaX70c{Bi\2e{ZYPvcYV{ MU[yN|I5PDh2OB?=
HTK NG[3W4xHfW6ldHnvckBCe3OjeR?= NVvZOIZvPDByIH7N NXW5fop3PzJiaB?= NEfQRXFqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v Mn\QNlMzQDRyMEK=
HTK NVfRV|h3TnWwY4Tpc44hSXO|YYm= NF\keWEyODBvOECwcm0> MVS3NkBp NEPkVYdjdG:la4OgWGdHNc7{4pETTY5lfWOnZDDSU3Mh[W6mIFiyU|LDqEGlY4XteYxifGmxbh?= MXeyN|I5PDByMh?=
Caco-2  M17wdGZ2dmO2aX;uJGF{e2G7 NUPYT5NHOSEEtV5CpC=> MkjPNlQhcA>? NVG2T5NG\GWlcnXhd4V{KFOHUmSgdJJwfGWrbjDlfJBz\XO|aX;u NI\3SIczOzF7NUC3NC=>
HeLa MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHG1SVYyODBibl2= NHvnbGEzPCCq M3jKdmROW09? NGDre2RKSzVyIH;mJFExOG6P MWKyN|E3PTd2OB?=
HeLa MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVyyfmlqPDBibl2= MmjYOFghcA>? NVrrS|U2TE2VTx?= MnXDTWM2OCCxZjC0NI5O M{DHOVI{OTZ3N{S4
HeLa NGL6S4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\wNlAhdk1? Mn\JO|IhcA>? MlvqSG1UVw>? NXriRXZ4UUN3MDDv[kAzOG6P M3HDfFI{OTZ3N{S4
HeLa NEnmUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWKxNE8{OC93MDDuUS=> NIPjfVg4OiCq MnLMSG1UVw>? NGHQUWhqdmO{ZXHz[ZMhfGinIH71cYJmeiCxZjDNUXAhMM7WzrjtLUBtd3O|IHPlcIx{KGSxc3Wg[IVx\W6mZX70cJk> NGHSU3ozOzF4NUe0PC=>
MDA-MB-231 NXX6[GxRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nldlI2NTRyMDDuUS=> Mnz1OFghcA>? M1L1VWlEPTBib3[gNlY{NjKwTdMg NGX3U2czOzB3NUG5PC=>
MCF-7  Mo\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTPOoZQOjVvNECwJI5O MmTPOFghcA>? MX7JR|UxKG:oIEKyNE41dk1? MU[yN|A2PTF7OB?=
ECC-1  NGjkUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjkToMyODBibl2= M2rVS|I1KGh? MUPleIhidm:u MkHObY5kemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIFxd3C2b4TpZ{BvfWOuZXmgeI8hOzVn MVuyN|AzQDhyMx?=
HEC-1A MkjzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvTNVAxKG6P M4LVT|I1KGh? NULBXnNq\XSqYX7vcC=> NEDheYhqdmO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[XCxcITveIlkKG63Y3zlbUB1dyB|OTW= M2LSfVI{ODJ6OECz
NHAC-kn MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLrTHQzOTBxMUCwM|UxOCCwTR?= MnXDNVIhcA>? MkXMSG1UVw>? MYjJR|UxKG:oIEWwNI5O M{G2S|I{ODF5OEex
A549 M3ntdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfQUHozPTBibl2= MWS2MVczKGh? MmruSG1UVw>? Mnv4Z4F2e2W|IHGg[5Jm[XSncjDpcohq[mm2b4L5JIVn\mWldDDjc41jcW6nIIfpeIghXFiWIH;yJIVzdG:2aX7pZi=> MlXvNlI6QTR5OEC=
MG-63 NWrlVllqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrUN|AxKG6P M{LiWFEzKGh? M3vzW2ROW09? NWS4PWJocW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJJRwKDh4JR?= M3i2WlIzPzl7M{O4
MG-63 MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDSN|AxKG6P NW\0XWZNOjRiaB?= NVHrRZRHTE2VTx?= M4HsNolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A3PyV? M{i0V|IzPzl7M{O4
MG-63 NF\ObI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHP6TWY{ODBibl2= Mnn4OFghcA>? NX\ZWplTTE2VTx?= MlzlbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIITvJFU3LQ>? MUGyNlc6QTN|OB?=
HL60  NGmwdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvhdnVDOTVyLUO1NEBvVQ>? MVyyOEBp NVLaZ4pHcW6lcnXhd4V{KGOnbHygZZBweHSxc3nzxsB4cGWwIHPvcoNmdnS{YYTpc45{KGirZ3jldkB1cGGwIEK1NEBvVQ>? M3LsWFIzPzV|N{O5
U937 M{C0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rk[VE2OC1|NUCgcm0> NWPmVVdPOjRiaB?= MXXpcoNz\WG|ZYOgZ4VtdCCjcH;weI9{cXQEoIfo[Y4h[2:wY3XueJJifGmxboOgbIlocGW{IIToZY4hOjVyIH7N MlfZNlI4PTN5M{m=
SCC-6 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW[yNFAuOzJyMDDuUS=> NWSzVGhpOTJxMkSvOFghcA>? MXzEUXNQ MVnpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? MUKyNlU2OjN{MR?=
U87  NUK1cXVST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXmxNFAuOzByIH7n MWCyOEBp M4LucolvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A4OiViIHH0JFIxOG6p NVPa[HhUOjJ{N{C4OFk>
K562 M1jpRmZ2dmO2aX;uJGF{e2G7 MVyxJO69VQ>? NF\r[5cyOiCq M3vE[WROW09? NWfqZnhl\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> MX[yNlE4QTF7OB?=
Reh MmDiSpVv[3Srb36gRZN{[Xl? NYfIOmFuOC5|L{Gg{txO M1HneVEzKGh? M2HPNWROW09? Mlnn[Y5p[W6lZYOgeIhmKGW6cILld5Nqd25ib3[gVnVPYDNiaX7keYNm\CCkeTC1MYF7[S2FZGK= M3n4[|IzOTd7MUm4

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • 濃度: Dissolved in absolute ethanol, final concentrations ~10 μM
  • 反応時間: 96 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • 製剤: Dissolved in DMSO
  • 投薬量: ~5 mg/kg/day
  • 投与方法: Injection s.c.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
体内 順序で溶剤を入れること:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
3mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 302.4
化学式

C17H22N2O3

CAS No. 58880-19-6
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02959905 Recruiting Metastatic Melanoma BGI, China|Sun Yat-sen University December 2016 Phase 1
NCT02486965 Recruiting Fibromyalgia University Hospital, Brest October 2015 --
NCT01954433 Recruiting Glenohumeral Arthritis and/or Rotator Cuff Tear Arthropathy (TSA)|Rotator Cuff Tear (RCR)|Trapeziometacarpal Osteoarthritis (TMC OA) Matthias Flury|Winterthur Institute of Health Economics (WIG), Switzerland|Schulthess Klinik November 2013 --
NCT01575106 Unknown status Pain Massachusetts General Hospital June 2012 --
NCT02762903 Completed Osteoarthritis Columbia University August 2009 --
NCT00914173 Completed Pain Medasense Biometrics Ltd November 2008 --

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • 回答:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC信号経路図

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Trichostatin A (TSA)を買う | Trichostatin A (TSA) ic50 | Trichostatin A (TSA)供給者 | Trichostatin A (TSA)を購入する | Trichostatin A (TSA)費用 | Trichostatin A (TSA)生産者 | オーダーTrichostatin A (TSA) | Trichostatin A (TSA)化学構造 | Trichostatin A (TSA)分子量 | Trichostatin A (TSA)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID